The evidence that AMPA-induced intracellular Zn<sup>2+</sup> dysregulation causes movement disorder via nigrostriatal dopaminergic neurodegeneration suggests that AMPA receptors, probably Ca<sup>2+</sup>- and Zn<sup>2+</sup>-permeable GluR2-lacking AMPA receptors are potential targets for overcoming Parkinson's syndrome.